These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 39396256)

  • 1. Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.
    Chen S; van den Brink MRM
    Best Pract Res Clin Haematol; 2024 Sep; 37(3):101566. PubMed ID: 39396256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off the shelf T cell therapies for hematologic malignancies.
    McCreedy BJ; Senyukov VV; Nguyen KT
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
    Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
    Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Del Bufalo F; Quintarelli C
    Haematologica; 2024 Jun; 109(6):1689-1699. PubMed ID: 38832424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
    Lv Z; Luo F; Chu Y
    Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
    Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
    Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic CAR-T cells for cancer immunotherapy.
    Chen X; Gao Y; Zhang Y
    Immunotherapy; 2024; 16(16-17):1079-1090. PubMed ID: 39378059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
    Kang Y; Li C; Mei H
    J Hematol Oncol; 2024 May; 17(1):29. PubMed ID: 38711046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic CAR Cell Therapy-More Than a Pipe Dream.
    Caldwell KJ; Gottschalk S; Talleur AC
    Front Immunol; 2020; 11():618427. PubMed ID: 33488631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
    Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
    Moradi V; Omidkhoda A; Ahmadbeigi N
    Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
    Khurana A; Lin Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
    Martínez Bedoya D; Dutoit V; Migliorini D
    Front Immunol; 2021; 12():640082. PubMed ID: 33746981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?
    Watanabe N; Mamonkin M
    Cancer J; 2021 Mar-Apr 01; 27(2):176-181. PubMed ID: 33750078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.